2023
Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network
Clark J, Garvey W, Niswender K, Schmidt A, Ahima R, Aleman J, Battarbee A, Beckman J, Bennett W, Brown N, Chandler‐Laney P, Cox N, Goldberg I, Habegger K, Harper L, Hasty A, Hidalgo B, Kim S, Locher J, Luther J, Maruthur N, Miller E, Sevick M, Wells Q. Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network. Journal Of The American Heart Association 2023, 12: e027693. PMID: 36752232, PMCID: PMC10111504, DOI: 10.1161/jaha.122.027693.Peer-Reviewed Original ResearchConceptsAmerican Heart AssociationHeart AssociationWeight loss interventionNovel therapeutic approachesVanderbilt University Medical CenterUniversity Medical CenterEffective therapeutic interventionsField of obesityResearch NetworkLoss interventionClinical trialsWorldwide prevalenceMedical CenterTherapeutic approachesObesityTherapeutic targetAnimal modelsJohns Hopkins University SchoolTherapeutic interventionsIndividual centersNew targetsUniversity of AlabamaOverweightUniversity SchoolIntervention
2016
Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema
Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H, Yu C, Banerji A, Brown NJ. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. Journal Of Allergy And Clinical Immunology 2016, 140: 242-248.e2. PMID: 27913306, PMCID: PMC5705179, DOI: 10.1016/j.jaci.2016.09.051.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaResolution of symptomsVisual analog scaleAnalog scaleReceptor antagonistTreatment groupsBradykinin BEnzyme (ACE) inhibitor-associated angioedemaStudy drug administrationReceptor antagonist icatibantHours of presentationTreatment of attacksC1 inhibitor deficiencyBradykinin receptor antagonismFrequency of administrationVanderbilt University Medical CenterUniversity Medical CenterMassachusetts General HospitalTwo-thirdsAntagonist icatibantBowel edemaWhite patientsH2 blockersClinical efficacyInhibitor deficiencyHigh-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial
Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, Brown NJ. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. JAMA 2016, 315: 877. PMID: 26906014, PMCID: PMC4843765, DOI: 10.1001/jama.2016.0548.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedAged, 80 and overAspartate AminotransferasesAtorvastatinCardiac Surgical ProceduresCreatinineDouble-Blind MethodDrug Administration ScheduleFemaleGlomerular Filtration RateHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMedication AdherenceMiddle AgedPostoperative ComplicationsRenal Insufficiency, ChronicConceptsAcute kidney injuryMorning of surgerySerum creatinine concentrationPlacebo groupCardiac surgeryStatin treatmentAtorvastatin groupKidney injuryClinical trialsCreatinine concentrationAcute Kidney Injury Following Cardiac SurgeryAdult cardiac surgery patientsCardiac surgery patientsChronic kidney diseaseHours of surgeryPostoperative day 2Day of surgerySafety monitoring boardVanderbilt University Medical CenterUniversity Medical CenterAtorvastatin dailyStatin therapyAtorvastatin treatmentSurgery patientsKidney disease
2013
Pollen Count and Presentation of Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Straka B, Nian H, Sloan C, Byrd JB, Woodard-Grice A, Yu C, Stone E, Steven G, Hartert T, Teo KK, Pare G, McCarty CA, Brown NJ. Pollen Count and Presentation of Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema. The Journal Of Allergy And Clinical Immunology In Practice 2013, 1: 468-473.e4. PMID: 24565618, PMCID: PMC4042396, DOI: 10.1016/j.jaip.2013.05.003.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaRate of angioedemaSeasonal allergiesRamipril Global Endpoint TrialAngiotensin converting enzyme (ACE) inhibitorsEnzyme (ACE) inhibitor-associated angioedemaIncidence of angiotensinMonths of presentationAdverse drug eventsDate of presentationVanderbilt University Medical CenterUniversity Medical CenterMarshfield Clinic Personalized Medicine Research ProjectOngoing TelmisartanEndpoint trialsACE inhibitorsPollen countsDrug eventsAssociated angioedemaObservational studyCohort analysisMedical CenterHospital settingAngioedemaPersonalized Medicine Research ProjectThe Effect of Reducing Maximum Shift Lengths to 16 Hours on Internal Medicine Interns’ Educational Opportunities
Theobald CN, Stover DG, Choma NN, Hathaway J, Green JK, Peterson NB, Sponsler KC, Vasilevskis EE, Kripalani S, Sergent J, Brown NJ, Denny JC. The Effect of Reducing Maximum Shift Lengths to 16 Hours on Internal Medicine Interns’ Educational Opportunities. Academic Medicine 2013, 88: 512-518. PMID: 23425987, PMCID: PMC3638874, DOI: 10.1097/acm.0b013e318285800f.Peer-Reviewed Original ResearchConceptsDuty hour restrictionsMaximum shift lengthsInternal medicine internsHour restrictionsVanderbilt University Medical CenterUniversity Medical CenterCommon presenting problemMedicine internsMore patientsUnique patientsInpatient encountersMorning report conferencesMedian numberMedical CenterProgress notesClinical exposureProcedural experienceShift lengthPresenting problemPatientsMore historyHoursExposureAttendanceInterns